ClinicalTrials.gg
TerminatedNCT04031885Updated Aug 24, 2021Results posted

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

A Phase 4 interventional study of Abemaciclib and Fulvestrant in Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Terminated at 61 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-24.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Why this study was terminated
Business decision based on the inability to enroll subjects into the trial

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Enrollment
50th of 55
4 · median 120
Started
2019
with 2 others
Phase 4
8 of 55
4 open now
Registered
18th of 55
by date
Lead sponsor
17 of 55
Eli Lilly and Company

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 50th largest by enrollment, is one of 3 that started in 2019, is one of 8 in phase 4, and was the 18th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The reason for this study is to compare the efficacy of abemaciclib, in combination with fulvestrant, to that of physician's choice of chemotherapy in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has spread to internal organs. Your participation in this trial could last up to 31 months, depending on your cancer type and how you and your tumor respond.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be females of status with HR+, - breast cancer that has spread to internal organs
  • Participants must have had at least one endocrine therapy
  • Participants must be willing to use a device to answer daily questions about how they are doing for the duration of their participation in the study
  • If participant has diarrhea from a previous treatment, they should talk to their doctor to ensure they have recovered enough to participate in this study

Exclusion criteria

Exclusion Criteria:

  • Participants must not have breast cancer that has spread to the brain if untreated and with symptoms
  • Participants must not have had any systemic treatment after their breast cancer has spread unless it is endocrine therapy
  • Participants must not have certain active infections including or hepatitis
  • Participants must not be pregnant or breastfeeding
  • Participants must not have certain types of cancers or certain previous cancer treatments
  • Participants must not have certain serious medical conditions, including heart or lung disease, or have had certain types of tissue or organ transplants
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Abemaciclib + Fulvestrant

    150 milligram (mg) Abemaciclib given orally twice a day (BID) with 500 mg fulvestrant given by intramuscular (IM) injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), then Day 1 of each subsequent cycle.

    Drug: Abemaciclib · Drug: Fulvestrant

  • Active comparator
    Standard Chemotherapy

    Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label.

    Drug: Standard Chemotherapy

Interventions

  • Administered orally

    Also known as: LY2835219

  • Administered IM

  • Standard chemotherapy of physician's choice administered according to product label.

    Also known as: Capecitabine, Docetaxel, Nab paclitaxel, Paclitaxel

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)

    ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to the corresponding treatment arm \[intent-to-treat (ITT) population\], based on investigator-assessed tumor responses.CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking in reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Confirmations of CR and PR are not required.

    Time frame: Randomization to Measured Progressive Disease (Up to 12 Months)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from first dose date until the first occurrence of documented disease progression per Response Criteria In Solid Tumors version 1.1(RECIST v1.1) or death from any cause in the absence of progressive disease. Progression-free survival will be based on investigator-assessed tumor responses; there will not be an independent central review of imaging data.

    Time frame: First Dose Date to Objective Progression or Death Due to Any Cause (Up to 12 Months)

  2. Time to Response (TTR)

    TTR is defined as the time from first dose date until the date that measurement criteria for CR or PR (whichever is first recorded) are first met, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: First Dose to Date of CR or PR (Up to 12 Months)

  3. Duration of Response (DoR)

    DoR is defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or documented disease progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence.

    Time frame: Date of CR or PR to Date of Objective Progression or Death Due to Any Cause (Up to 12 Months)

  4. Progression Free Survival 2 (PFS 2)

    PFS 2 is defined as the time from first dose date to the disease progression date on next line (first line of post-discontinuation treatment), or starting date of the second line of post-discontinuation treatment or death from any cause, whichever is earlier, or death from any cause, whichever is earlier.

    Time frame: Randomization to Second Objective Progression or Death Due to Any Cause (Up to 12 Months)

07

Results

Posted Aug 24, 2021
Limitations and caveats
This study was terminated early as a business decision based on the inability to enroll subjects into the trial.

Participant flow

The study was terminated early as a business decision based on the inability to enroll subjects into the trial.

Participant flow — Overall Study
MilestoneAbemaciclib + FulvestrantStandard Chemotherapy
Started13
Received any quantity of study treatment11
Completed13
Not completed00

Outcome measures

PrimaryObjective Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)

ORR is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the total number of participants randomized to the corresponding treatment arm \[intent-to-treat (ITT) population\], based on investigator-assessed tumor responses.CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking in reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. Confirmations of CR and PR are not required.

Time frame:
Randomization to Measured Progressive Disease (Up to 12 Months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)
percentage of participantsAbemaciclib + FulvestrantStandard Chemotherapy
Objective Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)00
SecondaryProgression Free Survival (PFS)

PFS is defined as the time from first dose date until the first occurrence of documented disease progression per Response Criteria In Solid Tumors version 1.1(RECIST v1.1) or death from any cause in the absence of progressive disease. Progression-free survival will be based on investigator-assessed tumor responses; there will not be an independent central review of imaging data.

Time frame:
First Dose Date to Objective Progression or Death Due to Any Cause (Up to 12 Months)

No measurements were reported for this outcome.

SecondaryTime to Response (TTR)

TTR is defined as the time from first dose date until the date that measurement criteria for CR or PR (whichever is first recorded) are first met, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Time frame:
First Dose to Date of CR or PR (Up to 12 Months)

No measurements were reported for this outcome.

SecondaryDuration of Response (DoR)

DoR is defined as the time from the date that measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or documented disease progression is observed, per RECIST 1.1 criteria, or the date of death from any cause in the absence of documented disease progression or recurrence.

Time frame:
Date of CR or PR to Date of Objective Progression or Death Due to Any Cause (Up to 12 Months)

No measurements were reported for this outcome.

SecondaryProgression Free Survival 2 (PFS 2)

PFS 2 is defined as the time from first dose date to the disease progression date on next line (first line of post-discontinuation treatment), or starting date of the second line of post-discontinuation treatment or death from any cause, whichever is earlier, or death from any cause, whichever is earlier.

Time frame:
Randomization to Second Objective Progression or Death Due to Any Cause (Up to 12 Months)

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abemaciclib + Fulvestrant1/1 (100%)1/1 (100%)1/1 (100%)
Standard Chemotherapy1/3 (33.3%)0/3 (0%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventAbemaciclib + FulvestrantStandard Chemotherapy
DehydrationMetabolism and nutrition disorders1/10/3
Most frequent other events
Showing 10 of 58
Most frequent other events
EventAbemaciclib + FulvestrantStandard Chemotherapy
TachycardiaCardiac disorders1/10/3
DyspepsiaGastrointestinal disorders1/10/3
NauseaGastrointestinal disorders1/11/3
VomitingGastrointestinal disorders1/11/3
Clostridium difficile infectionInfections and infestations1/10/3
Decreased appetiteMetabolism and nutrition disorders1/11/3
DehydrationMetabolism and nutrition disorders1/11/3
ArthralgiaMusculoskeletal and connective tissue disorders1/11/3
Muscular weaknessMusculoskeletal and connective tissue disorders1/10/3
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/10/3

Baseline characteristics

All randomized participants.

Age, Categorical
Age, Categorical(Participants)Abemaciclib + FulvestrantStandard ChemotherapyTotal
<=18 years000
Between 18 and 65 years112
>=65 years022
Sex: Female, Male
Sex: Female, Male(Participants)Abemaciclib + FulvestrantStandard ChemotherapyTotal
Female134
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Abemaciclib + FulvestrantStandard ChemotherapyTotal
Hispanic or Latino000
Not Hispanic or Latino134
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Abemaciclib + FulvestrantStandard ChemotherapyTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White123
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Abemaciclib + FulvestrantStandard ChemotherapyTotal
United States134
08

Study locations

61 sites
  • Scottsdale Healthcare Hospitals
    Avondale, Arizona 85392, United States
  • University of Arizona Cancer Center
    Phoenix, Arizona 85004, United States
  • Yuma Regional Cancer Center
    Yuma, Arizona 85364, United States
  • CARTI Cancer Center
    Little Rock, Arkansas 72205, United States
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • Compassionate Cancer Care Medical Group Inc
    Corona, California 92879, United States
  • Chan Soon- Shiong Institute for Medicine
    Costa Mesa, California 92627, United States
  • Chan Soon- Shiong Institute for Medicine
    El Segundo, California 90245, United States
  • Compassionate Cancer Care Medical Group Inc
    Fountain Valley, California 92708, United States
  • St. Joseph Heritage Healthcare
    Fullerton, California 92835, United States
  • Scripps Clinic
    La Jolla, California 92037, United States
  • UCLA Medical Center
    Los Angeles, California 90024, United States
  • TRIO - Translational Research in Oncology-US, Inc.
    Los Angeles, California 90095, United States
  • Univ of California Irvine College of Medicine
    Orange, California 92868, United States
  • Comprehensive Cancer Centers of the Desert
    Palm Springs, California 92262, United States
  • Desert Hematology Oncology Medical Group
    Rancho Mirage, California 92270, United States
  • Emad Ibrahim, MD, INC
    Redlands, California 92373, United States
  • Compassionate Cancer Care Medical Group Inc
    Riverside, California 92501, United States
  • University of California, Davis - Health Systems
    Sacramento, California 95864, United States
  • Torrance Memorial Medical Center
    Torrance, California 90505, United States
  • Banner MD Anderson Cancer Center
    Greeley, Colorado 80631, United States
  • Hartford Hospital
    Hartford, Connecticut 06102-5037, United States
  • Millennium Oncology
    Hollywood, Florida 33024, United States
  • Ocala Oncology, P.A.
    Ocala, Florida 34474, United States
  • Tallahassee Memorial Cancer Center
    Tallahassee, Florida 32308, United States
  • Cleveland Clinic of Florida
    Weston, Florida 33331, United States
  • Candler Medical Oncology Practice
    Savannah, Georgia 31405, United States
  • Tift Regional Health System Anita Stewart Oncology Center
    Tifton, Georgia 31794, United States
  • Kaiser Permanente Center for Health Research
    Honolulu, Hawaii 96819, United States
  • Saint Alphonsus Regional Medical Center
    Boise, Idaho 83706, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Touro Infirmary
    New Orleans, Louisiana 70115, United States
  • Willis-Knighton Cancer Center
    Shreveport, Louisiana 71103, United States
  • York Hospital
    York, Maine 03909, United States
  • Reliant Medical Group, Inc.
    Worcester, Massachusetts 01608, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Baptist Cancer Center
    Oxford, Mississippi 38655, United States
  • St. Francis Medical Center
    Grand Island, Nebraska 68803, United States
  • Oncology Hematology West
    Omaha, Nebraska 68130, United States
  • OptumCare Cancer Care
    Las Vegas, Nevada 89102, United States
  • Carol Simon Cancer Center at Overlook Medical Center
    Summit, New Jersey 07901, United States
  • Brooklyn Methodist Hospital
    Brooklyn, New York 11215, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • SUNY At Stony Brook
    Stony Brook, New York 11794, United States
  • White Plains Hospital
    White Plains, New York 10601, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cancer Care Associates of York
    York, Pennsylvania 17403, United States
  • Womens and Infants
    Providence, Rhode Island 02905, United States
  • Baptist Cancer Center
    Memphis, Tennessee 38120, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Oncology Consultants, P.A.
    Houston, Texas 77030, United States
  • Renovatio Clinical
    The Woodlands, Texas 77380, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • Providence Regional Cancer Partnership
    Everett, Washington 98201, United States
  • Cancer Care Northwest
    Spokane, Washington 99202, United States
  • Centro Integrado de Cancer del Sur, PSC
    Coto Laurel, 00780, Puerto Rico
  • Bella Vista Oncology Group
    Mayaguez, 00680, Puerto Rico
  • Ponce Medical School
    Ponce, 00716, Puerto Rico
  • Centro de Cancer de la Mujer
    Ponce, 00717, Puerto Rico
  • Clinical Research Puerto Rico, Inc.
    San Juan, 00909, Puerto Rico
  • Fundacion de Investigacion de Diego
    San Juan, 00927, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Aug 2020, 11 months.

Results were first posted in Aug 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2019
First posted
Jul 24, 2019
StartActual
Aug 14, 2019
Primary completionActual
Aug 11, 2020
CompletionActual
Aug 11, 2020
Results first posted
Aug 24, 2021
Last update
Aug 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04031885
Responsible party
Sponsor
First posted
Jul 24, 2019
Start date
Aug 14, 2019
Primary completion
Aug 11, 2020
Completion
Aug 11, 2020
Results posted
Aug 24, 2021
Last update
Aug 24, 2021

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abemaciclib · Fulvestrant

Start the discussion